House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Pulmonology

Global strategy for asthma management and prevention — 2026

GINA · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

This focused House summary highlights diagnosis, age-specific controller and reliever decisions, reassessment and acute-care priorities in GINA 2026. It includes the new anti-inflammatory-reliever options for school-age children and updated acute oxygen guidance. Asthma control includes both current symptoms and future attacks; infrequent symptoms do not establish low risk. Detailed inhaler-specific doses, severe-asthma biologic selection and preschool emergency protocols remain in their dedicated sections.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Confirm asthma and assess risk

  • In adults, adolescents and school-age children, confirm a compatible variable symptom history with variable expiratory airflow, preferably before starting inhaled corticosteroid treatment. More than one test may be needed. If spirometry is unavailable, use peak flow rather than symptoms alone. [1]
  • For adult bronchodilator responsiveness, GINA retains an increase from baseline in FEV1 or FVC of at least 12% and 200 mL. For children aged 6–17 years, the FEV1 criterion is at least 12% of predicted. These different denominators must not be interchanged. [1]
  • With typical symptoms but unavailable or negative spirometry/peak-flow testing, elevated FeNO or eosinophils can support Type 2 asthma. Other diseases can raise these markers, and low values do not exclude asthma; do not use a biomarker alone as the diagnosis. [1]
  • Assess symptom control and exacerbation risk separately. Previous attacks, SABA-only treatment or overuse, poor adherence, incorrect technique, low lung function and smoking can confer risk despite few symptoms. Record lung function at diagnosis, after 3–6 months of treatment and periodically thereafter. [1]

Use an ICS-containing regimen

  • For adults, adolescents and children aged 6–11 years, do not treat asthma with SABA alone. Use an inhaled-corticosteroid-containing regimen to reduce severe exacerbations and control symptoms; this recommendation does not substitute the separate preschool pathway. [1]
  • For adults and adolescents, preferred Track 1 uses low-dose ICS-formoterol as reliever: as-needed-only treatment at Steps 1–2, and maintenance plus reliever treatment at Steps 3–5. Only ICS-formoterol combinations have the evidence for this ICS-LABA reliever role. [1]
  • For adults/adolescents when Track 1 is not possible, or when already stable with good adherence and no attack in the past year, Track 2 is an alternative. At Step 1, take low-dose ICS with each SABA use, preferably combined. At later steps, distinguish the maintenance inhaler from the ICS-SABA or SABA reliever and assess adherence carefully. [1]
  • Before stepping up treatment, confirm that symptoms are from asthma and address technique, adherence, exposure and comorbidities. Do not use ICS-formoterol as the reliever alongside a different maintenance ICS-LABA, because evidence for that combination’s safety and efficacy is lacking. [1]
  • After good asthma control for 2–3 months, consider gradual step-down to the lowest effective treatment, with a written plan, close monitoring and follow-up. Do not completely withdraw ICS except for a short diagnostic trial when necessary. Low/medium/high-dose categories do not imply equivalent potency between products. [1]

Keep school-age and preschool pathways separate

  • For children aged 6–11 years, Step 1 now includes as-needed low-dose ICS-formoterol or ICS-SABA, using combination or separate ICS/SABA inhalers. At Step 2, daily ICS with as-needed SABA remains an option, with AIR-only regimens suggested as alternatives. [1]
  • For children aged 6–11 years, evidence does not yet establish whether as-needed ICS-formoterol is as effective as daily ICS with SABA at Step 2. MART is an established option at Steps 3–4 using lower-dose formulations; children uncontrolled on Step 4 despite good technique/adherence need expert assessment. [1]
  • For children aged 5 years or younger, diagnosis is clinical and requires recurrent wheeze or a wheezing episode with interval symptoms, no likely alternative cause, and a timely response to asthma therapy. If criteria are incomplete, use a provisional suspected-asthma diagnosis and reassess; a first wheezing episode in an infant under 12 months is usually bronchiolitis. [1]
  • For diagnosed asthma in children aged 5 years or younger, use inhaled SABA for day-to-day relief. Start daily controller treatment, preferably ICS, if symptoms occur more than twice weekly or there was a severe attack requiring unscheduled care in the previous year. Review response, technique, adherence and alternatives before changing treatment. [1]

Support effective treatment and specialist escalation

  • Choose an inhaler the patient can use correctly and afford, teach technique and check it repeatedly. For a pressurized metered-dose inhaler, a spacer improves lung delivery and reduces local ICS adverse effects; rinse and spit after ICS. [1]
  • Give every patient a written, digital or pictorial asthma action plan matched to age, literacy, maintenance treatment and reliever. State how to change treatment and when to seek help; patients with a history of rapid deterioration should obtain immediate medical assessment when worsening begins. [1]
  • Before labelling adult/adolescent asthma severe, confirm the diagnosis and optimize adherence, high-dose ICS-LABA and contributory factors. Persistent disease warrants expert phenotype assessment and appropriate add-on treatment. Maintenance oral corticosteroids are a last resort because of cumulative harms; stop ineffective add-ons. [1]

Assess attacks and treat while arranging escalation

  • For an acute attack in adults, adolescents or children aged 6–11, assess breathing, saturation and airflow while starting indicated treatment. Transfer severe attacks immediately; drowsiness, confusion or a silent chest warrants intensive-care assessment. Use an age-appropriate validated severity score in children. [1]
  • When asthma and anaphylaxis occur together, give epinephrine first and then immediately start inhaled bronchodilator treatment. Bronchodilation does not replace treatment of anaphylaxis. [1]
  • In acute asthma for adults, adolescents and children aged 6–11, supplemental oxygen is suggested when saturation is below 92% (when awake in children) and should be titrated to 92–95%. Adjust for altitude and recognize that oximetry can overestimate saturation in darker skin. Do not withhold needed oxygen because oximetry is unavailable. [1]
  • For acute asthma, reassess after initial bronchodilator treatment rather than automatically repeating doses. Titrate further SABA to clinical and lung-function response. Excessive SABA can cause hypokalaemia, arrhythmias and lactic acidosis with hyperventilation that may be mistaken for worsening asthma. [1]
  • For moderate or severe exacerbations in adults, adolescents and children aged 6–11, introduce systemic corticosteroids early. The adult prednisone/prednisolone course is 40–50 mg/day for 5–7 days; for children aged 6–11, 1–2 mg/kg/day, maximum 40 mg/day, for 3–5 days. Review progress before stopping. [1]
  • Do not routinely order chest radiographs or prescribe antibiotics for an asthma exacerbation. Investigate suspected alternative pathology or an atypical/nonresponsive course. Consider intravenous magnesium for a severe attack that does not respond to initial treatment. [1]

Reduce the chance of another attack

  • Before discharge after an exacerbation, start or continue ICS-containing therapy, check technique and adherence, and return reliever use to as-needed. Adult/adolescent MART with ICS-formoterol is preferred where suitable; patients already using MART should resume it and do not need additional SABA. [1]
  • Arrange early review after every exacerbation: the primary-care pathway suggests about 2–7 days for adults and 2–5 days for children, adjusted to clinical and social circumstances. Recheck recovery, risk factors and the written plan. Even one severe exacerbation should trigger review of preventive treatment and cumulative oral-steroid exposure. [1]

Limitations and use

  • This is a focused guide, not a complete acute-care algorithm. Preschool acute wheeze, intensive-care management, pregnancy, occupational asthma and biologic eligibility require their specific guidance.
  • Reliever and maintenance doses depend on age, inhaler formulation and delivered versus metered dose. Use the current GINA dose tables and local product approval; seek medical review when reliever use exceeds the plan’s threshold.
  • GINA 2026 adds school-age AIR options, but comparative evidence at Step 2 and the best transitions between paediatric steps remain incomplete. Adult treatment tracks must not be copied directly into preschool care.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Global strategy for asthma management and prevention — 2026

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
GINA
Resource type
Clinical guideline · House clinical summary

Earlier House summaries: asthma in adults gina

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Confirm asthma and assess risk
  • Use an ICS-containing regimen
  • Keep school-age and preschool pathways separate
  • Support effective treatment and specialist escalation
  • Assess attacks and treat while arranging escalation
  • Reduce the chance of another attack
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House